Saturday, 31 October 2026European Markets

CTP And FIDUCIAL REAL EST. Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - ctp (ctpnv.as) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
ctp (ctpnv.as) €16.36 3.42% 15.96%
fiducial real est. (oria.pa) €181.00 1.88% 6.67%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ctp (ctpnv.as)

3.42% forward dividend yield and 15.96% return on equity

ctp n.v., together with its subsidiaries, develops, owns, operates, and leases commercial real estate properties in central, western, and eastern europe. it offers industrial properties for various applications, such as warehousing, manufacturing, research and development, and bespoke property applications. the company also develops city-center office campuses and parks. in addition, it is involved in the solar energy business. the company was founded in 1998 and is headquartered in amsterdam, the netherlands. ctp n.v. operates as a subsidiary of ctp holding b.v.

earnings per share

as for profitability, ctp has a trailing twelve months eps of €2.2.

pe ratio

ctp has a trailing twelve months price to earnings ratio of 7.44. meaning, the purchaser of the share is investing €7.44 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.96%.

dividend yield

as stated by morningstar, inc., the next dividend payment is on sep 2, 2024, the estimated forward annual dividend rate is 0.58 and the estimated forward annual dividend yield is 3.42%.

volatility

ctp's last week, last month's, and last quarter's current intraday variation average was a negative 0.97%, a positive 0.14%, and a positive 1.00%.

ctp's highest amplitude of average volatility was 1.40% (last week), 1.07% (last month), and 1.00% (last quarter).

sales growth

ctp's sales growth for the current quarter is 11.2%.

more news about ctp.

2. fiducial real est. (oria.pa)

1.88% forward dividend yield and 6.67% return on equity

fiducial real estate sa operates and manages real estate properties in france. its property portfolio includes office, business, and residential buildings. the company is headquartered in courbevoie, france.

earnings per share

as for profitability, fiducial real est. has a trailing twelve months eps of €12.43.

pe ratio

fiducial real est. has a trailing twelve months price to earnings ratio of 14.56. meaning, the purchaser of the share is investing €14.56 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.67%.

volatility

fiducial real est.'s last week, last month's, and last quarter's current intraday variation average was 0.57%, 0.14%, and 0.86%.

fiducial real est.'s highest amplitude of average volatility was 0.57% (last week), 0.86% (last month), and 0.86% (last quarter).

revenue growth

year-on-year quarterly revenue growth declined by 1.6%, now sitting on 86.26m for the twelve trailing months.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 15, 2024, the estimated forward annual dividend rate is 3.3 and the estimated forward annual dividend yield is 1.88%.

more news about fiducial real est..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com